Polar Communications has invested NIS 9 million in Mediwound to acquire a 6% stake in the company.
Based in Yavne, Mediwound develops Debrase Gel Dressing for treating burns and is the exclusive licensee of two patents that cover the extraction and purification process of Debrase. It is currently completing Phase II/b clinical trials in burn centers in the EU and the US.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>